Prevail Therapeutics Inc. Common Stock
PRVL
PRVL was delisted on the 21st of January, 2021.
46 hedge funds and large institutions have $427M invested in Prevail Therapeutics Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 6 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 8
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
30% more capital invested
Capital invested by funds: $328M → $427M (+$99.5M)
10% more funds holding
Funds holding: 42 → 46 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.67M |
| 2 |
BlackRock
New York
|
+$3.41M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.28M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$979K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$911K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$3.67M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.84M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$1.25M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.11M |
| 5 |
Millennium Management
New York
|
-$618K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Victory Capital Management
San Antonio,
Texas
| – | -$16K | -1,343 | Closed |
|
PRVL Hedge Fund Activity: Q4 2019 in Review
46 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q4 2019, worth a combined $427M — up 30% from $328M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new PRVL positions and 6 closed out — a net gain of 4 holders — while 15 added to existing stakes and 8 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $4.67M. The largest seller was Clal Insurance, cutting an estimated $3.67M.
- 46 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q4 2019, up from 42 in Q3 2019.
- Funds reported $427M of Prevail Therapeutics Inc. Common Stock stock for Q4 2019, up 30% quarter-over-quarter.
- 10 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q4 2019 and 6 closed out, a net change of +4 holders.
- The largest Prevail Therapeutics Inc. Common Stock buyer in Q4 2019 was Point72 Asset Management, an estimated $4.67M added.
- The largest Prevail Therapeutics Inc. Common Stock seller in Q4 2019 was Clal Insurance, an estimated $3.67M sold.
Based on aggregated 13F filings for Q4 2019.